Hualan Bio founded in 1992, is a national high-tech enterprise engaged in the research, development, production and sales of plasma products, vaccines and recombinant Protein drugs. The company has a registered capital of 1.829 billion yuan, industries in 6 provinces and cities, more than 30 subsidiaries, 2 listed companies, total assets of 5.5 billion yuan, market value of more than 60 billion yuan. The company is the birthplace of the world's first listed influenza A (H1N1) vaccine, and the only domestic enterprise that has passed the WHO pre-certification of influenza vaccine. The company has fully passed the quality, environment, occupational health and safety ‘ISO’ management system certification, has a number of independent intellectual property rights, ‘Hualan’ trademark has been recognised as a well-known trademark in China, and the leading products are leading the domestic industry with the advantages of production scale, variety specifications, market share and brand influence. The leading products are leading the development of domestic industry with their production scale, variety and specification, market share and brand influence.
